This Content Is Only For Subscribers
The opioid epidemic continues to have a devastating impact across the United States, claiming thousands of lives each year. Among the most effective treatments for opioid use disorder (OUD) is medication-assisted treatment (MAT), which combines medications like buprenorphine and methadone with counseling and therapy to support recovery. However, despite the proven effectiveness of MAT, barriers to accessing treatment have long existed — particularly through prior authorization requirements imposed by insurers. In a significant and highly anticipated move, the Michigan Department of Health and Human Services (MDHHS) recently announced the removal of prior authorization requirements for MAT drugs in Medicaid plans, a change that will make it easier for people with OUD to access lifesaving treatment.
This victory comes as part of a broader effort by behavioral health providers across the country to eliminate prior authorization requirements for MAT, a process that has faced resistance in both the public and private sectors. The elimination of these requirements in Michigan signals a major step forward in expanding access to addiction treatment and highlights the growing push for policy reforms that prioritize patient care over bureaucratic hurdles.
What Is Medication-Assisted Treatment (MAT) and Why Is It Important?
Before diving into the details of Michigan’s new policy, it’s essential to understand what MAT is and why it’s critical for individuals struggling with opioid use disorder. MAT has been shown through decades of research to be the most effective approach for treating OUD. It involves the use of medications such as buprenorphine, methadone, and naltrexone to help individuals manage the symptoms of withdrawal and reduce cravings, while counseling and behavioral therapy work to address the psychological aspects of addiction. MAT has been proven to lower the risk of overdose, decrease criminal activity, reduce the transmission of infectious diseases like HIV and Hepatitis C, and improve long-term recovery outcomes.
Despite these proven benefits, accessing MAT has long been a challenge for many individuals. One of the major obstacles to receiving timely treatment has been the prior authorization process. Before a patient can receive MAT, health insurance companies often require providers to submit documentation and receive approval for the treatment, which can delay the start of care and create unnecessary roadblocks in the recovery process.
The Prior Authorization Problem
Prior authorization is a practice that requires healthcare providers to obtain approval from an insurance company before delivering a specific treatment or service. The goal is typically to ensure that the treatment is medically necessary and aligns with the insurance provider’s policy guidelines. However, for behavioral health providers and patients alike, prior authorization has proven to be a significant barrier to accessing MAT.
For patients struggling with opioid use disorder, waiting for prior authorization can be a life-or-death matter. Treatment for OUD often requires immediate intervention, especially when individuals are motivated to begin treatment and are ready to stop using opioids. Delays caused by prior authorization can prevent patients from receiving the help they need when they are most vulnerable. This delay can lead to an increased risk of relapse, overdose, and death.
Brooke Feldman, manager of the CleanSlate Outpatient Addiction Medicine center in Philadelphia, highlighted the frustrations of both providers and patients with the prior authorization process. At the Payer’s Behavioral Health Management and Policy Summit in Washington, D.C., Feldman spoke candidly about how the process slows down access to MAT. “Prior authorizations really are a nightmare,” she said. “They often are just to protect costs, but I promise you the person who walks away from treatment services because of a prior authorization delay, he’s still using drugs and costing you a lot more money.” This statement underscores the fact that delayed treatment not only affects individual patients, but also has significant long-term consequences for public health systems and insurance companies themselves.
Michigan’s Groundbreaking Decision
In a groundbreaking announcement, the Michigan Department of Health and Human Services declared that it would eliminate prior authorization requirements for MAT medications in its Medicaid program, effective immediately. This decision is a direct response to the ongoing push by behavioral health providers to improve access to MAT for individuals with OUD.
“By eliminating this requirement, medical providers will be empowered to help people begin treatment when they are ready and increase their chances of a successful recovery,” said Joneigh Khaldun, Chief Medical Executive and Chief Deputy for Health for MDHHS, in a press release. With this change, Medicaid beneficiaries in Michigan will now have greater access to crucial medications like buprenorphine, which is used to diminish opioid withdrawal symptoms and cravings. For many patients, this medication is the first step toward recovery, and removing prior authorization barriers ensures that they can begin their treatment as soon as they are ready, without unnecessary delays.
This change is particularly significant because Michigan has been hit hard by the opioid crisis. The state has seen an alarming number of overdose deaths in recent years, and any policy that facilitates faster access to treatment could have a significant impact on public health outcomes. By eliminating prior authorization, the state is not only improving the treatment landscape for individuals with OUD but also sending a message that the healthcare system must prioritize access to care over administrative roadblocks.
The National Movement for MAT Access
Michigan is not the first state to take action against prior authorization requirements for MAT. In fact, 21 other states have already removed prior authorization requirements for Medicaid beneficiaries seeking MAT, further reflecting a growing national movement to increase access to opioid use disorder treatments. This shift is driven by a recognition that MAT is an essential tool in the fight against the opioid epidemic, and making it more accessible could help save countless lives.
In 2018, Pennsylvania Governor Tom Wolf announced an agreement with seven major insurers in the state to eliminate prior authorization requirements for MAT. This was a landmark decision, and it received praise from the American Medical Association (AMA), which urged other states to follow Pennsylvania’s lead. However, despite this progress, the removal of prior authorization for MAT has not been as widespread in the commercial sector, where insurers often impose more stringent requirements.
As the push for easier access to MAT continues to grow, advocates hope that more states and private insurers will follow suit. The decision in Michigan represents a significant victory, but it is just one part of a larger effort to remove barriers to addiction treatment nationwide.
Benefits of Removing Prior Authorization
Removing prior authorization requirements for MAT drugs is a win not only for patients but also for healthcare providers, insurance companies, and society as a whole. For patients, the immediate benefit is increased access to treatment. They no longer need to wait for approval before receiving the medications that can help them manage withdrawal symptoms and start their recovery journey.
For healthcare providers, the removal of prior authorization means fewer administrative hurdles and less time spent navigating bureaucratic processes. This allows them to focus more on delivering high-quality care and supporting patients through their recovery.
For insurers, removing prior authorization can ultimately lead to lower long-term costs. While prior authorization is intended to protect insurers from unnecessary expenditures, the delays it causes often result in more expensive consequences down the line. As Feldman pointed out, patients who are delayed in receiving MAT often relapse, resulting in higher medical costs due to overdose, emergency room visits, and other complications.
Finally, on a societal level, increasing access to MAT can help reduce the devastating effects of opioid addiction, including overdose deaths, criminal activity, and the spread of infectious diseases. By making MAT more accessible, states like Michigan are taking a crucial step toward reducing the harm caused by the opioid epidemic and improving public health outcomes.
Conclusion
Michigan’s decision to eliminate prior authorization for MAT medications in its Medicaid program is a major step forward in the fight against the opioid epidemic. This policy change is a victory for behavioral health providers and advocates who have been pushing for greater access to treatment and a reduction in administrative barriers that delay care. By ensuring that patients with opioid use disorder can access the medications they need without unnecessary delays, Michigan is setting an example for other states and private insurers to follow. As more states embrace this approach, the hope is that we can make a significant dent in the opioid crisis and save more lives.
